PNC-27 5mg Research Peptide

PNC-27 5mg is a synthetic 27–amino acid research peptide derived from the third alpha-helical segment of the tumor suppressor protein p53 (ASPP2 region). It has been studied in laboratory and preclinical models for its potential ability to selectively interact with cancer cell membranes through binding to human double minute 2 (HDM-2) protein. PNC-27 5mg is supplied strictly for laboratory research use and is not approved for human or animal use.

What Is PNC-27 5mg?

PNC-27 5mg is an experimental peptide originally synthesized around the year 2000 during research related to immunodeficiency studies. Subsequent investigations identified its potential interaction with HDM-2, a protein reported to be overexpressed on the plasma membranes of various cancer cell types. Unlike many anticancer research compounds that induce apoptosis, PNC-27 has been examined for its ability to induce necrotic cell death through direct membrane disruption in experimental models.

PNC-27 5mg remains an experimental research peptide used exclusively in controlled scientific environments.

Research Background

Research into PNC-27 has focused on its selective activity toward cancer cells observed in laboratory studies. HDM-2 protein has been reported to localize on the membranes of certain cancer cells but not on normal, non-transformed cells. This distinction led researchers to investigate whether PNC-27 could selectively bind cancer cell membranes while sparing normal cells.

Multiple in vitro and animal studies have examined PNC-27 in cancer cell lines including pancreatic cancer, ovarian cancer, leukemia, and breast tumor models. These findings are preclinical and have not been validated in human clinical trials.

Mechanisms of Research Interest

HDM-2 Binding and Selectivity

PNC-27 5mg has been studied for its ability to form a 1:1 complex with membrane-bound HDM-2, a step proposed to be critical for initiating downstream membrane-disruptive events in cancer cells.

Membrane Pore Formation

Experimental observations suggest that PNC-27 may participate in the formation of transmembrane pores, resulting in physical perforation of cancer cell membranes. This process has been associated with membranolysis, allowing ion influx and efflux of intracellular contents in research models.

Necrotic Cell Death Research

Unlike apoptosis-inducing compounds, PNC-27 has been examined for its ability to induce necrosis. Laboratory studies associate this mechanism with lactate dehydrogenase release, a marker of membrane disruption and cell lysis.

Peptide Integrity and Activity

Fluorescent labeling studies indicate that intact PNC-27 is required for membrane-disruptive activity. Research suggests that peptide fragments do not produce the same membranolytic effects, underscoring the importance of structural integrity.

Selectivity Toward Cancer Cells

Immuno-electron microscopy studies have visualized ring-shaped pore structures on cancer cell membranes exposed to PNC-27. These structures were not observed in normal cells unless HDM-2 protein was artificially introduced, supporting research hypotheses of selective activity.

All mechanisms described are experimental observations or theoretical models and do not imply clinical or therapeutic benefit.

Molecular and Chemical Information

• Product Name: PNC-27 5mg

• Peptide Length: 27 amino acids

• Origin: p53 (ASPP2) alpha-helical segment

• Form: Lyophilized powder

• Purity: Research-grade (greater than 99%)

Research Applications

PNC-27 5mg may be utilized by qualified researchers in laboratory investigations involving:

• Cancer cell membrane biology research

• HDM-2 protein interaction studies

• Necrotic cell death pathway research

• Membrane pore formation and cytolysis models

All use must remain within controlled laboratory environments.

Regulatory Status and Use Disclaimer

• For research use only

• Not approved by the Food and Drug Administration

• Not intended for human or veterinary use

• Not intended to diagnose, treat, cure, or prevent any disease

• No established clinical safety, dosing, or efficacy data